Drug Trial Radar · NCT00701129
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
Last checked: Nov 20, 2026Latest source record: May 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
Oct 2009
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy, clinical benefits and safety of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa (Myozyme®) in patients with infantile-onset Pompe disease. The objectives were to assess the efficacy of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa, as assessed by anti-recombinant human acid alpha-glucosidase (anti-rhGAA) antibody titers, and antibodies that inhibit the activity and/or uptake of alglucosidase alfa; to evaluate the clinical benefit as measured by overall survival, ventilator-free survival, left ventricular mass index (LVMI), gross motor function and development, disability index and the incidence of adverse events (AEs), serious adverse events (SAEs), and clinical laboratory abnormalities.
Conditions
- Pompe Disease
- Glycogen Storage Disease Type II
Interventions
Alglucosidase AlfaBiological
Administered as IV infusion.
MethotrexateDrug
Administered subcutaneously.
RituximabDrug
Administered as IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of StudyTime frame: Baseline, End of Study (up to Week 79 or early termination)
- Number of Patients With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of StudyTime frame: End of study (up to Week 79)
- Number of Patients Who Survived at End of StudyTime frame: Baseline up to End of study (Week 79)
- Number of Patients With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of StudyTime frame: End of study (up to Week 79 or early termination)
- Number of Patients With Ventilator Use at End of StudyTime frame: End of study (up to Week 79 or early termination)
- Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of StudyTime frame: End of study (up to Week 79 or early termination)
- Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of StudyTime frame: End of study (up to Week 79 or early termination)
- Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of StudyTime frame: End of study (up to Week 79 or early termination)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kosair Children's Hospital
Louisville, Kentucky
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.